by Raynovich Rod | May 29, 2013 | Clinical Diagnostics and Tools
Rayno Diagnostics and Tools Portfolio Rayno Life Science top picks were up 20 to 53% beating the NASDAQ and S&P. Five new stocks were added in 2013: BG Medicine (BGMD), Genomic Health (GHDX), Hologic (HOLX), Vermillion (VRML). One major trend is larger cap...
by Raynovich Rod | May 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Impressive Rally in Diagnostics and Tools Stocks The NASDAQ rally is beginning to fade now up only 17 pts after hitting a high of 3510 at 10 am EDT. However many Life Science Tools and Diagnostics stocks are having a strong day. We recently featured 3 micro-cap...
by Raynovich Rod | May 15, 2013 | BIOgraph, Clinical Diagnostics and Tools
Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 Update The synergies between diagnostics and drugs are growing as more treatment options require better data for cost-effective, targeted...
by Raynovich Rod | May 9, 2013 | BIOgraph, Clinical Diagnostics and Tools
Vermillion Gets Equity Infusion from Oracle Partners, Others: VRML Soars 36% By popular demand and continuing interest in three emerging micro-cap stocks we are updating coverage. This is triggered by news that saavy life science investors are making an initial...
by Raynovich Rod | May 7, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Rayno Diagnostics and Tools-Awaiting Q1 Results Many Rayno Diagnostics and Tools stocks have made new highs recently despite the sector being less frothy than biopharmaceuticals. These stocks are more pinned to financial results and dependent on a steady stream of new...
by Raynovich Rod | May 2, 2013 | Clinical Diagnostics and Tools, Reading List
Genomic Health Up 5% on Higher Q1 Revenues An article in the New York Times today (May 2) by Gina Kolata reviewed studies that affirmed the genetic basis of cancer. Genetic analysis of hundreds of tumors for endometrial cancer and leukemias found patterns of genetic...
by Raynovich Rod | Apr 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
A Great Quarter for Many Tools and Diagnostic Stocks The tools and diagnostics sector usually underperforms biopharmaceuticals because the companies are more tethered to deal news and fundamentals. We will review our focus stocks below as Q1 earnings come in. NASDAQ...
by Raynovich Rod | Apr 15, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph, Clinical Diagnostics and Tools, Macro
Gold Crash Spooks Traders-Life Science Stocks Lose Resilience IBB ($166.82) Down 1.6% Rayno Life Science Stocks- Quick Look With NAZ at 2343 We have not made any Rayno Portfolio changes but have added two stocks recently: Genomic Health (GHDX) and Hologic (HOLX) both...
by Raynovich Rod | Apr 10, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Blow Through New Highs The Rayno Biopharma stocks continued their run today and some Tools/DX stocks are freshening up. Yesterday we added Hologic (HOLX) as a turnaround/value play and it is up 1.73%. Other Rayno winners in this lagging sector...
by Raynovich Rod | Apr 9, 2013 | BIOgraph, Clinical Diagnostics and Tools
Hologic (HOLX) Offers Good Long Term Value We will add Hologic Inc. to our Diagnostics and Tools Portfolio. Prior to its acquisition by Hologic we had GenProbe Inc. on our focus list. Hologic (HOLX $21.70), Market Cap of $5.84B, offers good long term value with a...